SBS Law invites investors to lead a securities‑fraud class action against Capricor Therapeutics, highlighting a broader pattern of similar shareholder‑rights actions
Executive summary: Schall, Brown & Schwartz LLP announced that investors can apply to serve as lead plaintiffs in a class action lawsuit accusing Capricor Therapeutics of violating federal securities laws. The notice underscores Capricor’s legal exposure and fits into a broader pattern of SBS filing similar shareholder‑class actions against multiple public companies.
Who is involved: Schall, Brown & Schwartz LLP (SBS), Capricor Therapeutics (NASDAQ: CAPR), and affected shareholders.
Likely next: Shareholders have until September 28, 2026 to file lead‑plaintiff applications; the court will later decide on class certification and the parties may proceed to settlement or trial.
Schall, Brown & Schwartz LLP issued a press release reminding Capricor Therapeutics shareholders of their opportunity to seek lead‑plaintiff status in a putative class action alleging violations of Sections 10(b) and 20(a) of the Exchange Act. The notice comes amid a wave of comparable SBS‑initiated alerts for other public companies, suggesting the firm is actively pursuing securities‑fraud claims across multiple sectors. While the announcement does not allege new wrongdoing, it signals ongoing legal exposure for Capricor and reflects a coordinated effort by SBS to aggregate shareholder litigation.
Timeline
- — CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law (PR Newswire)
- — LII Investors Have Opportunity to Join Lennox International, Inc. Fraud Investigation with SBS Law (PR Newswire)
- — MO Investors Have Opportunity to Join Altria Group, Inc. Fraud Investigation with SBS Law (PR Newswire)
- — GPGI, Inc. Investor Alert: Contact SBS by September 15, 2026 for Opportunity to Lead Securities Fraud Lawsuit (PR Newswire)
Analysis — what this means
Likely next events
- September 28, 2026 deadline for lead‑plaintiff applications in the Capricor securities‑fraud class action
- August 31, 2026 deadline for investors to contact SBS regarding a potential lead‑plaintiff role in the Insulet Corporation investigation
- September 15, 2026 cutoff for shareholders to reach out to SBS about leading the GPGI (formerly CompoSecure) class action
Sectors affected
- Biotechnology
- Pharmaceuticals
Regulatory implications
- Potential enforcement of SEC Rule 10b‑5 and Section 10(b) of the Exchange Act
- Increased scrutiny of periodic disclosures by biotech companies
Historical parallels
- Earlier SBS reminders for Capricor on August 21, 2026 and August 17, 2026 regarding the same securities‑fraud class action
- Previous SBS investor alert for Genius Group Limited on August 24, 2026 offering a lead‑plaintiff opportunity
Key entities
Sources
Open the full interactive case file on Beyond →